Heat Biologics and University of Miami Developing Proprietary COVID-19 Diagnostic Test Under Collaborative Research Agreement

Test being designed to provide rapid, point-of-care diagnosis within 30 minutes Heat Biologics, Inc., a clinical-stage biopharmaceutical company specialized in the development of novel therapeutic and prophylactic vaccines, including one for coronavirus COVID-19, today reported that it is collaborating with the University of Miami to develop a proprietary UM COVID-19 point-of-care diagnostic test. The new, ["]

The post Heat Biologics and University of Miami Developing Proprietary COVID-19 Diagnostic Test Under Collaborative Research Agreement appeared first on Outbreak News Today.